Shares of Bristol Myers Squibb Co. BMY slid 1.43% to $57.38 Wednesday, on what proved to be an all-around mixed trading ...

Healthcare is considered a defensive industry, since good medical care is needed regardless of economic or market conditions.

Approvals last year included rare disease treatments, new oncology drugs, Eli Lilly’s Kisunla, and Mesoblast's Ryoncil.

Looking for undervalued stocks? We identified the top undervalued stocks in March 2025. Check out the list here.

Just take a look at the healthcare sector. By all accounts, healthcare stocks should be in the dumps. The sector sold off ...

This was the stock's fifth consecutive day of gains.

Eli Lilly releases cheaper vials of the weight-loss drug for self-paying patients and cuts the price of two existing doses.

Bristol-Myers Squibb released financial results for Q4 2024. Check out why I am upgrading BMY stock's rating from 'Buy' to ...

We recently published a list of Dividend Stock Portfolio For Income: Top 10 Stocks to Buy. In this article, we are going to ...

Bristol Myers' Opdivo plus Yervoy gets FDA Priority Review for first-line MSI-H/dMMR metastatic colorectal cancer, with a ...

The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult ...

Stock analysts at Zacks Research dropped their Q1 2025 earnings per share (EPS) estimates for Bristol-Myers Squibb in a note ...